Category Archives: Erudition & Culture

A study by Orsolya Kiss, PhD, a research scientist at SRI International, investigated how sleep duration, social media use, and brain activity interact in adolescents. The findings suggest a complex interplay between these factors, potentially impacting brain development.

Beckman Coulter, a leading clinical diagnostics company, announced the U.S. Food and Drug Administration (FDA) clearance of its Access NT-proBNP assay. This new test aids in diagnosing heart failure and assessing its severity in just under 11 minutes on the DxI 9000 Immunoassay Analyzer.

Diving into the exciting world of pharmacogenomics (PGx), a field that utilizes genetic testing to understand how an individual’s genes influence their response to medications.

Delving into the ongoing debate surrounding calcium and its potential link to an increased risk of cardiovascular disease (CVD), particularly when consumed through supplements.

Venture capital firms are the lifeblood of many biotech startups, providing not only vital financial resources but also operational expertise. This article dives into ten prominent venture capital arms established by pharmaceutical and biotechnology companies, highlighting their investment philosophies and areas of focus.

A new report by the Expert Group on Future Skills Needs (EGFSN) predicts significant growth in Ireland’s biopharmaceutical industry. The report, titled “Skills for Biopharma,” estimates the creation of 21,000-26,000 new biopharma jobs by 2027. This expansion builds upon the sector’s consistent growth over the past five years.

The European Medicines Agency (EMA) has released a revised question-and-answer document to aid manufacturers, regulators, and notified bodies involved with medical devices used alongside medications. This document offers practical guidance on implementing regulations for these combination products.

Researchers are exploring a novel approach combining a genetically modified herpes virus with a cancer vaccine. This combination therapy holds promise for treating aggressive childhood cancer.

Bayer presented promising data from their Phase III OASIS clinical trials on Elinzanetant, a potential new weapon in the fight against hot flashes and other menopause symptoms. Elinzanetant is a non-hormonal medication designed to address moderate to severe vasomotor symptoms (VMS), the technical term for hot flashes.

The trials, OASIS 1 and 2, were resounding successes. Elinzanetant not only met all its primary endpoints, but significantly reduced the frequency and severity of hot flashes compared to a placebo after just 4 and 12 weeks of treatment. This translates to potentially quicker relief for women experiencing these disruptive symptoms. The benefits of Уlinzanetant extended beyond just hot flashes. The trials also showed improvements in sleep disturbances and menopause-related quality of life in participants, suggesting a more holistic approach to managing this phase of life.

Semaglutide, a medication initially used for type 2 diabetes, has emerged as a potential game-changer in various healthcare fields. Let’s explore its expanding horizon: